How to beat jet lag: Tips from 4 high-flying elites who travel the world for work
Strategies like supplements, caffeine, or naps can help, but don't fix the root cause of jet lag.
To reduce brain fog and fatigue, realign your internal clocks with strategic light exposure.
"Jet lag is no big deal," I thought to myself, booking a flight to Austria for my first-ever trip to Europe earlier this summer. I'll just chug some coffee and power through.
Nearly a week after I've returned, my internal clock is still in shambles. My body's alarm rings at 5 a.m. and by 8:30 p.m. an irresistible urge to sleep kicks in. My usual "afternoon slump" at work now kicks in before lunch, and midday meetings feel like a fight for my life to stay awake.
Don't make my mistake — jet lag can cause brain fog, excessive fatigue, moodiness, and digestive issues, which can prevent you from staying focused and making quick, clear decisions.
But there's a better way to travel, according to people who do it constantly for work and still arrive ready to perform their best.
To prepare for next time, I asked for advice from frequent fliers — from a pro athlete who competes across timezones to a CEO who takes meetings across the world. Here's what really works, according to science, and how you can get back to peak performance faster after a long flight.
The entrepreneur behind a popular jet lag app says light is the best defense
Mickey Beyer-Clausen, a 50-year-old Danish entrepreneur, is the co-founder and CEO of the Timeshifter app for reducing jet lag.
Now based in New York, he all but grew up on a plane as his mom worked for Scandinavian Airlines. His subsequent career has forced him to grappled with the strain of crossing time zones.
"I started traveling more and more and for business, and I'm not 20 anymore. I really struggle with jet lag," he told Business Insider.
Jet lag happens when there's a disparity between your surrounding time zone and your internal clocks (yes, plural — research has found different systems and tissues keep time separately, with the brain as a sort of overseer).
Working with the top researchers on circadian rhythms (the natural 24-hour cycles of the body), Beyer-Clausen found reducing jet lag is all about realigning the brain's master clock so it can "act as the conductor of the orchestra of all the clocks you have in the body."
One of the biggest timing cues for your brain is light, which signals it's time to be alert, while seeing darkness tells the brain to wind down and get ready for rest.
If Beyer-Clausen is traveling from New York to Copenhagen, six hours ahead, he'll prepare by seeing morning light earlier and earlier in the days before his flight. He also adjusts his nighttime routine to be earlier by avoiding light sooner — that includes no phone screens. He creates a dark room for sleep at 10 p.m. and then 9 p.m. compared to his usual bedtime of 11 p.m.
An executive coach plans ahead to switch time zones before traveling
Julian Hayes II, a 39-year-old executive coach based in Tennessee, who regularly travels internationally, and constantly works with frequent fliers.
He has an involved routine of fasting on the plane and exercising on arrival to fend off jeg lag symptoms. But his biggest recommendation is to prevent jet lag in the first place by getting acclimated to a new time zone early.
A few days before a flight, he shifts his sleeping schedule about 30 minutes at a time to more closely align to where he's traveling.
A good rule is that it takes about one day per time zone you're crossing to get acclimated. A trip from New York to Europe, for instance, might take you about six days to recover from completely.
A pro athlete swears by the 'NBA nap' and basic supplements
For NBA star Kevin Love of the Miami Heat, travel is a constant part of his schedule, and his job depends on showing up physically and mentally dialed in. For instance, he might play a game in sunny, southern, East Coast Miami then fly two times zones over to Minnesota for a game a day later. A key part of his health routine is the "NBA nap," a quick snooze before a game to boost alertness.
Love supercharges his nap by drinking an espresso just before dozing which, according to him, ensures that he wakes up fully energized after about 20 to 30 minutes. For peak performance, he follows up with a freezing shower, based on research that cold showers can boost alertness and mood.
"I don't do it every day but I do ice-cold showers when I need to really wake up and get that, boom, dopamine hit," Love said. "My mind is working at a very high level as well as my body being just refreshed."
While Love's coffee-sleep-icy shower strategy can help you feel better in the moment, they don't address the root cause of jet lag.
The true star of Love's regimen is how he unwinds.
He has magnesium and tart cherry juice, two natural ingredients that can improve sleep quality and recovery after exercise. Love also takes supplements with melatonin, a hormone that your body naturally produces to make you sleepy.
Melatonin is the only supplement that helps the underlying problem of jet lag, Beyer-Clausen, the jet lag app founder, told me. That's because the body isn't sure when to produce the melatonin you need to fall asleep.
If you're struggling to adapt to your new schedule and short on natural melatonin to get you to sleep, store bought is fine. Just be mindful the product you choose actually contains melatonin and in the right dose (experts typically recommend 1-3 mg).
A private jet nutritionist eats low-carb breakfasts and low-fat dinners to curb fatigue
Jenna Daou's job is all about helping elite jet setters minimize any disruption to their routines by providing custom-designed, nutritionally-balanced meals for travel.
As a nutritionist for private jet company VistaJet, she's picked up a few pointers for healthy eating in the air.
"Your digestive system and metabolism are linked to your internal clock, and when and what you eat can either help realign your circadian rhythm or throw it further off," Daou told BI.
Eating for the local time zone can help mitigate symptoms of fatigue, she said. For instance, she aims for high-protein, low-carb breakfasts to promote stable blood sugar, and high-carb, low fat meals in the evening for good digestion, relaxation, and natural melatonin production.
Daou said she keeps her meals light when she's flying, and sticks to her usual habits of getting plenty of protein and fresh fruit during the day, and winding down at night with a cup of herbal tea and a book.
"Consistency is something I really value in my routine, it keeps me grounded, especially when I'm traveling," she said. "I do my best to recreate that same sense of calm and familiarity, even when I'm flying overnight."
Read the original article on Business Insider

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
INBRAIN Neuroelectronics Reports Interim Analysis of First-in-Human Study of Graphene Brain-Computer Interface
Graphene-based BCI demonstrates high-resolution brain decoding and mapping in patients undergoing tumor resection at the Manchester Centre for Clinical Neurosciences Initial four patient cohort has shown no safety concerns to date that would prevent the completion of this first-in-human study. BARCELONA, Spain, July 29, 2025--(BUSINESS WIRE)--INBRAIN Neuroelectronics today announced the interim analysis of findings from the world's first-in-human clinical study of its graphene-based brain-computer interface (BCI) technology. The study, sponsored by the University of Manchester and conducted at the Manchester Centre for Clinical Neurosciences (Northern Care Alliance NHS Foundation Trust), is evaluating the safety and functional performance of graphene-based electrodes when used during surgery for resection of brain tumors. The primary objective of the study (NCT06368310) is to assess the safety of INBRAIN's brain-computer interface (BCI) during brain tumor surgery. Secondary objectives include evaluating the quality of neural signals captured by the device, its ability to deliver targeted brain stimulation, the consistency of its performance throughout the procedure, and its overall suitability for use in the neurosurgical operating room. A total of 8 to 10 patients are expected to be enrolled to validate the safety and functional performance of the graphene-based BCI. The study design included an interim analysis after the first four patients had been recruited to ensure patient safety and data quality. Interim analysis of the results from the first cohort of four patients enrolled in the study demonstrated no device-related adverse events, a key component of the primary endpoint of the study. During awake language mapping, the device captured distinct high gamma activity linked to different phonemes, the smallest units of sound in speech, showcasing exceptional spatial and temporal resolution, even with micrometer-scale contacts. The ultra-thin, sub-micrometer graphene electrodes also proved compatible with commercially available, CE-marked electrophysiology systems, reliably recording real-time brain signals throughout the surgical procedures. "The ability to detect high-frequency neural activity with micrometer-scale precision opens new possibilities for understanding brain-tumor interactions and broader brain function in neuro-related disorders," said Mr. David Coope, Chief Investigator and Consultant Neurosurgeon at the Manchester Centre for Clinical Neurosciences, the Geoffrey Jefferson Brain Research Centre and the University of Manchester. "This technology could be transformative, not only for improving surgical outcomes but for unlocking new treatment pathways." Throughout the procedures, INBRAIN's BCI enabled high-resolution brain signal monitoring, addressing one of the most pressing challenges in neurosurgery: achieving precise tumor removal while preserving essential functions such as speech, movement, and cognition. The device was used in parallel with standard clinical monitoring tools, maintaining consistent performance across the surgical window. "This milestone demonstrates that graphene-based brain-computer interfaces can be deployed in the operating room and deliver a level of neural fidelity not achievable with traditional materials," said Carolina Aguilar, CEO and Co-Founder, INBRAIN Neuroelectronics. "We're moving toward a future where neurosurgeons and neurologists can rely on real-time, high-definition brain data to guide personalized interventions." INBRAIN's platform is powered by ultra-flexible, thin-film graphene semiconductors that conform more precisely to the brain surface than conventional strip electrodes. The BCI features high-density, multiscale, bidirectional contacts for superior decoding and modulation, and reduced graphene oxide (rGO) nanoporous matrices that enhance sensitivity and signal resolution. In preclinical studies, the GCI significantly outperformed platinum-based electrodes in detecting high gamma frequencies (80–130 Hz) critical for speech decoding, with statistical significance (p < 0.01). Clinical Advantages Graphene technology offers several benefits for neurosurgical procedures. It enhances surgical precision by enabling smaller and more densely packed electrodes, allowing surgeons to define and preserve critical functional areas during tumor resection. Its flexibility enables accurate decoding and mapping in anatomically complex or hard-to-access brain regions, including the walls of the tumor resection cavity. Additionally, the device's ability to decode high-frequency activity offers huge scientific opportunities including the potential to reveal in situ interactions between glioma cells and neurons, offering potential insights into new therapeutic targets for halting tumor progression. "We're not delivering incremental innovation, we're enabling entirely new capabilities," said Kostas Kostarelos, Co-Founder of INBRAIN and Chief Scientific Investigator of the study and Professor of Nanomedicine at the University of Manchester, the Catalan Institute of Nanoscience and Nanotechnology (ICN2) in Barcelona, and Programme Lead for the Next Generation Therapeutics Theme of the National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre (BRC). "This convergence of advanced materials science, neuroscience, and AI is shaping the future of real-time, precision neurology." As the first safety study of a graphene-based neural interface in humans, this study marks a foundational step toward the development of BCI therapeutic systems for chronic neurological diseases, pioneering a new era of real-time, precision neurology. About INBRAIN Neuroelectronics INBRAIN Neuroelectronics is pioneering real-time precision neurology with the world's first graphene-based brain-computer interface (BCI) therapeutics platform. Our technology combines precise BCI decoding with micrometric modulation to deliver adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By providing continuous real-time monitoring and autonomous therapy adjustments, our AI-driven platform maximizes therapeutic outcomes while minimizing side effects. Through strategic collaborations, including with Merck KGAa and our subsidiary INNERVIA Bioelectronics, we are extending our innovative solutions to peripheral nerve and systemic disease applications, unlocking the potential of neurotechnology and bioelectronics. For more information, visit and follow us on LinkedIn. About Northern Care Alliance (NCA) Northern Care Alliance NHS Foundation Trust provides hospital and community healthcare services in Salford, Oldham, Bury and Rochdale. Our dedicated team of around 20,000 staff delivers high standards of care and experience excellence to over one million people across Greater Manchester and beyond, working together to save lives and improve lives. More information about the NCA can be found at About the National Institute for Health and Care Research (NIHR) The mission of the National Institute for Health and Care Research (NIHR) is to improve the health and wealth of the nation through research. We do this by: Funding high quality, timely research that benefits the NHS, public health and social care; Investing in world-class expertise, facilities and a skilled delivery workforce to translate discoveries into improved treatments and services; Partnering with patients, service users, carers and communities, improving the relevance, quality and impact of our research; Attracting, training and supporting the best researchers to tackle complex health and social care challenges; Collaborating with other public funders, charities and industry to help shape a cohesive and globally competitive research system; Funding applied global health research and training to meet the needs of the poorest people in low and middle income countries. NIHR is funded by the Department of Health and Social Care. Its work in low and middle income countries is principally funded through UK international development funding from the UK government. About the NIHR Manchester Biomedical Research Centre (BRC) The NIHR Manchester Biomedical Research Centre (BRC) transforms scientific breakthroughs into diagnostic tests and life-saving treatments for patients. NIHR Biomedical Research Centres (BRCs) are collaborations between NHS organisations and universities. They bring together academics and clinicians to translate scientific discoveries into potential new treatments, diagnostics and technologies. Manchester BRC is hosted by Manchester University NHS Foundation Trust and The University of Manchester – in partnership with five NHS trusts; Blackpool Teaching Hospitals NHS Foundation Trust, The Christie NHS Foundation Trust, Greater Manchester Mental Health NHS Foundation Trust, Lancashire Teaching Hospitals NHS Foundation Trust, and the Northern Care Alliance NHS Foundation Trust. About The University of Manchester The University of Manchester is recognised globally for its pioneering research, outstanding teaching and learning, and commitment to social responsibility. The Russell Group institution is ranked the 6th best university in the UK and 38th in the world (Academic Ranking of World Universities). A truly international university, its community includes more than 44,000 students, 12,000 staff, and 500,000 alumni from 190 countries. Together, they are tackling the world's biggest challenges – the University's social and environmental impact is ranked in the top ten globally (Times Higher Education Impact Rankings). The University is a powerhouse of research and discovery; 25 Nobel laureates are among its former staff and students; and it was ranked fifth for research power – the quality and scale of research and impact – in the UK government's Research Excellence Framework (REF) 2021. The institution is the most popular in the UK for undergraduate applications (UCAS 2021 cycle), and it is the it is the most targeted university by the UK's leading employers (The Graduate Market, 2023). View source version on Contacts Media Kimberly HaKKH Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Relief Therapeutics Announces Proposed Business Combination with NeuroX, Successor to MindMaze
NeuroX recently acquired the assets and operations of MindMaze, a world-renowned leader in evidence-based neurotherapeutic solutions for neurological diseases and brain disorders Business combination to create an expanded, SIX-listed, commercial-stage, AI-driven, scalable health tech company Binding term sheet signed; transaction subject to customary conditions and approvals Closing expected in Q4 2025 GENEVA, SWITZERLAND / / July 29, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) ("Relief" or the "Company"), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced the execution of a binding term sheet for a proposed business combination with NeuroX Group SA ("NeuroX"), a privately held company that recently acquired the assets and operations of MindMaze - a recognized leader in digital neurotherapeutics and brain health technologies. The envisaged combination aims to create a publicly listed, AI-based therapeutics platform integrating software-delivered, disease-modifying clinical interventions with pharmacological treatments and a comprehensive brain health platform to improve the quality of life of patients, caregivers and families. NeuroX will contribute a clinically validated, risk-mitigated portfolio supported by multiple milestones achieved across technological development, regulatory approvals, and market access, as well as a solid network of pharmaceutical partners. Dr. Raghuram Selvaraju, chairman of the board of directors of Relief, commented: "By entering into this transaction, we intend to bring a global pioneer in digital neurotherapeutics to the public markets through the Relief ecosystem. NeuroX, which now operates the MindMaze platform, has a compelling business model, an established track record of innovation, and a distinctive technology that integrates neuroscience and digital therapeutics to address some of the most pressing challenges in neurology. We believe this combination has the potential to create significant value for patients, clinicians, and shareholders. Importantly, it offers existing Relief shareholders the opportunity to participate in the growth of a scalable enterprise with potential to become a multi-billion-dollar company." Alexandre Capet, head of corporate development of NeuroX, commented: "The business combination with Relief presents a timely opportunity to build on the vision and ambition set by MindMaze on a global scale, accelerating our market presence and next phase of growth. Over the past decade, we have built a robust portfolio of clinically validated digital neurotherapeutics and invested heavily in commercial infrastructure, AI technology, and R&D. With increased visibility and a solid foundation in place, we believe this transaction comes at a pivotal inflection point in our journey. It positions us to scale more effectively as a publicly listed company and expand the reach of our breakthrough therapies." NeuroX and MindMaze OverviewNeuroX is a Swiss-based, commercial-stage company. In 2025, NeuroX acquired the operations and intellectual property of the legacy MindMaze group ("MindMaze"), including the MindMaze ® brand. MindMaze has developed first-of-its-kind neurotherapeutics that provide disease-modifying motor and cognitive treatments for neurological diseases and brain disorders. These neurotherapeutics are delivered through proprietary software and hardware, underpinned by an advanced brain technology platform that integrates wearables and sensors, and provides digital assessments as well as telehealth services. The unique suite of MindMaze solutions is delivered globally across the continuum-of-care, both in-clinic and in patients' home, to successfully address some of neurology's major unmet needs. NeuroX has already partnered with leading pharmaceutical companies that use its proprietary technology across multiple clinical trials. Over the last decade, MindMaze has invested more than USD 350 million to establish clinical evidence, demonstrate significant medico-economic outcomes, and market MindMaze's disease-modifying therapeutic platform across neurological diseases, including stroke, Parkinson's disease, and at-risk aging. In the United States, MindMaze has received a unique reimbursement code (CAT-3) to support the delivery of its home-based neurotherapeutic training. Its R&D pipeline focuses on adjacent neurological diseases, such as spinal cord injury, multiple sclerosis, traumatic brain injury, and Alzheimer's disease/dementia. Moved by the mission to accelerate the brain's ability to recover, the MindMaze platform innovates by combining software-delivered behavioral treatments, drugs, devices, data, and AI to establish a new paradigm of precision medicine in neurology and neural repair. For more information, visit . Transaction OverviewUnder the terms of the term sheet, NeuroX shareholders will exchange at closing all outstanding shares of NeuroX for newly issued shares of Relief. The transaction is based on agreed equity valuations of CHF 100 million for Relief, representing a significant premium to its current market capitalization, and CHF 1 billion for NeuroX. Post-closing, Relief shareholders are expected to own approximately 9% of the combined entity on a fully diluted basis, with NeuroX shareholders holding the remaining 91%. The combined entity's shares will continue trading on the SIX Swiss Exchange. The term sheet provides for full exclusivity during the negotiation and finalization of a definitive agreement, as well as a customary break fee, reflecting the commitment of both parties to advance the transaction. It also includes a one-year post-closing reset mechanism to adjust the ownership ratio within certain parameters based on the combined entity's market value at that time. The transaction remains subject, among other customary conditions, to the negotiation and execution of a definitive agreement, completion of satisfactory due diligence, approval by the shareholders of both companies, completion of concurrent financing by NeuroX, filing of regulatory documentation with the applicable securities authorities, and receipt of regulatory and stock exchange approvals. There can be no assurance that the transaction will be completed on the terms described herein or at all. The parties expect to finalize the definitive transaction agreement in Q3 2025, with closing anticipated in Q4 2025. ABOUT RELIEFRelief is a commercial-stage biopharmaceutical company dedicated to advancing treatment paradigms and improving the lives of patients with rare and debilitating diseases. With core expertise in drug delivery systems and drug repurposing, Relief's clinical pipeline includes innovative treatments designed to address critical unmet medical needs in rare dermatological, metabolic and respiratory conditions. The Company has also successfully brought several approved products to market through licensing and distribution partnerships. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. The Company has access to a CHF 50 million equity commitment in the form of a share subscription facility with its largest shareholder, Global Emerging Markets (GEM). For more information, visit CONTACTRELIEF THERAPEUTICS Holding SAJeremy MeinenChief Financial Officercontact@ DISCLAIMERThis press release contains forward-looking statements, which may be identified by words such as "believe," "assume," "expect," "intend," "may," "could," "will," or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, but are not limited to, changes in economic conditions, market developments, regulatory changes, competitive dynamics, and other risks or changes in circumstances. This communication is provided as of the date hereof, and Relief undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise. The information provided on NeuroX and MindMaze within this press release is provided by NeuroX. Relief makes no representation or warranty as to the accuracy, completeness, or reliability of such information and disclaims any obligation or liability in connection with it. No offer or solicitation: This press release does not constitute (i) a prospectus within the meaning of the Swiss Financial Services Act or under any other applicable laws, (ii) a solicitation of proxy, consent or authorization with respect to any securities or in respect of the proposed business combination or (iii) an offer to sell, a solicitation of an offer to buy, or a recommendation to buy any security of Relief, NeuroX, or any of their respective affiliates. There shall not be any sale of any securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the laws of such other jurisdiction. This press release should not be treated as offering material of any sort and is for information purposes only. SOURCE: Relief Therapeutics Holding SA View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Medscape
an hour ago
- Medscape
Novel Long-term Findings for Post-HRT Fracture Risk
Bone fracture risk for women coming off menopausal hormone replacement therapy (HRT) increases sharply before showing a reduced long-term fracture risk compared with women who never took hormones, new data from a study published in The Lancet indicated. 'It's reassuring that long term, you didn't seem to be worse off if you had taken hormones in the past. And it reconfirms that when you first go off the hormones, you're going to lose some benefit, which can translate into higher fracture risk and that needs attention,' certified menopause specialist Deborah Kwolek, MD, told Medscape Medical News . 'I think this is a good wake-up call that we need to pay more attention to women's bone health starting at menopause,' said Kwolek, assistant professor at Harvard Medical School in Boston and founding lead of the Mass General Women's Health and Sex and Gender Medicine Program. Data on 3 Million Women Included Researchers, led by Yana Vinogradova, PhD, with the Centre for Academic Primary Care at the University of Nottingham in the United Kingdom, assessed the health records of 648,747 women aged 40 years and older, who were registered with a primary care practice between January 1, 1998, and February 28, 2023, and had a first record for any fracture. These women were matched at the fracture index date with up to five female controls (2,357,125 women) with no fracture history, who were the same age and registered at the same general practice. Menopausal HRT-related fracture risks were assessed using conditional logistic regression adjusted for demographics, family history, menopausal symptoms, comorbidities, and other medications. The study was powered to investigate all HRT prescriptions containing estrogen and progestogen in the British National Formulary and to assess risk estimates for up to 25 years after stopping therapy. Reduced Fracture Risk in Older Age 'Our study suggests that, even after stopping menopausal hormone therapy, women could benefit from notably reduced fracture risk in older age. This likelihood holds for those who might have used menopausal hormone therapy for shorter periods because of concerns such as breast cancer,' the authors wrote. These results differ in some ways from some previous large studies, including the Women's Health Initiative post-trial study, which followed 15,187 women for 5 years but found no increased fracture risk after stopping hormone therapy. Kwolek explained that estrogen has long been known to be important for bone health, especially in the perimenopausal to menopausal transition and estrogen could prevent the bone loss that increases right at menopause. But the general understanding had been that when women go off estrogen the benefits go away. 'We had been saying more recently that when women go off estrogen, there should be a plan for how their bone health may be addressed, potentially with medication and close monitoring,' Kwolek said. Consider Baseline Fracture Risk She added that it's important to consider what a patient's fracture risk is to start with. For a young, healthy woman who doesn't have osteoporosis, it's probably not terribly significant if her risk goes up a bit going off the hormones, Kwolek said, but 'for a woman who's 70 and she comes off her hormones and already has osteoporosis, the effects may be more significant,' Kwolek said. 'Maybe at that time you might start another medication to strengthen the bone.' She cautions against seeing the temporary increase in fracture risk after stopping the hormones as a reason not to start HRT in the first place. The strengths of this study include its large dataset and long follow-up, Kwolek said. It also calls attention to an area of women's care that too often is overlooked. Whether in primary care or gynecologic appointments, she said, 'people aren't paying as much attention to these transitions as I think they should,' Kwolek said.